Whilst these medicines offer significant therapeutic benefits, some patients report experiencing an unpleasant taste in their mouth during treatmentoften described as metallic, bitter, or simply 'off'
It is not used in hormone-sensitive cancers without specialist oversight
Some users experience headaches, appetite loss, or odd color changes in the skin
Compared to other OA models, MIA can rapidly induce pain-related phenotypes 25 , making it suitable for short-term studies
Kishimoto M, Noda M (2011) A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers
Body fat percentage directly measures what BMI tries to estimate indirectly